Ranjit Manchanda, Professor of Gynaecological Oncology, Wolfson Institute of Population Health, Consultant Gynaecological oncologist at Barts Health NHS Trust shared a post on LinkedIn:
“Delighted to see our paper on NBN and Ovarian Cancer Risk published in AJOG.
Our meta-analysis shows a clear association between an NBN pathogenic variant and ovarian cancer in the White-population, and this may be stronger with non-high-grade serous carcinoma compared to high-grade serous carcinoma.
NBN pathogenic variants could be combined with other non-genetic and genetic (polygenic-risk-score) ovarian cancer risk factors using complex ovarian cancer risk-prediction models going forward, to identify NBN-positive women at an ovarian cancer risk level above the risk threshold for offering surgical prevention.
For the commonest pathogenic variant, c.657_661del, the risk potentially approaches the threshold for surgical prevention. This could be a reason to include NBN in ovarian cancer gene panels going forward.
Congratulations to Subhasheenee Ganesan for her hard work on this paper.”
Title: Risk of ovarian cancer in women with a pathogenic or likely pathogenic variant in NBN: a systematic review and meta-analysis
Authors: Subhasheenee Ganesan, Lea Mansour, Amanda Dibden, Michail Sideris, Antonetta Malan, Samuel Oxley, Ashwin Kalra, Jacqueline Sia, Xia Wei, Priyanka Deshmukh, Hamda Mohamed, Robert D. Morgan, Nicola Flaum, Adam Brentnall, Caitlin T. Fierheller, D. Gareth Evans, Ranjit Manchanda
Read The Full Article
Other articles about NBN on OncoDaily.